Cargando…

EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM

BACKGROUND: Natriuretic peptide system (NPS) and renin angiotensin aldosterone system (RAAS) function oppositely at multiple levels. While it has long been suspected that angiotensin II (ANGII) may directly suppress NPS activity, no clear evidence to date support this notion. OBJECTIVES: This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Xiao, Iyer, Seethalakshmi R., Ma, Xiaoyu, Reginauld, Shawn H., Chen, Yang, Pan, Shuchong, Zheng, Ye, Moroni, Dante, Yu, Yue, Zhang, Lianwen, Cannone, Valentina, Chen, Horng H., Ferrario, Carlos M., Sangaralingham, S. Jeson, Burnett, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901178/ https://www.ncbi.nlm.nih.gov/pubmed/36747784 http://dx.doi.org/10.1101/2023.01.26.525806

Ejemplares similares

Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation
por: Ma, Xiao, et al.
Publicado: (2023)

Natriuretic peptide pathways in heart failure: further therapeutic possibilities
por: Sangaralingham, S Jeson, et al.
Publicado: (2022)

C-type natriuretic peptide: the heart’s guardian angel
por: Sangaralingham, S Jeson, et al.
Publicado: (2020)

A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts
por: Ichiki, Tomoko, et al.
Publicado: (2009)

M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
por: McKie, Paul M, et al.
Publicado: (2013)

M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics
por: McKie, Paul M., et al.
Publicado: (2014)

A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction
por: Lim, Soo Ghim, et al.
Publicado: (2013)

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
por: Tan, Nicholas Y., et al.
Publicado: (2021)

Cell Surface Protein Disulfide Isomerase Regulates Natriuretic Peptide Generation of Cyclic Guanosine Monophosphate
por: Pan, Shuchong, et al.
Publicado: (2014)

Chronic natriuretic peptide protein therapeutics
por: Chen, Horng H, et al.
Publicado: (2013)

C-Type natriuretic peptide: a potential urinary biomarker for renal remodeling and fibrosis during aging
por: Sangaralingham, Jeson S, et al.
Publicado: (2011)

Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension
por: Cannone, Valentina, et al.
Publicado: (2022)

Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease
por: Cannone, Valentina, et al.
Publicado: (2019)

A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure
por: Kawakami, Rika, et al.
Publicado: (2018)

Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis
por: Martin, Fernando L, et al.
Publicado: (2011)

In-Vivo Evaluation of an In Situ Polymer Precipitation Delivery System for a Novel Natriuretic Peptide
por: Lim, Soo Ghim, et al.
Publicado: (2013)

Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up
por: Buglioni, Alessia, et al.
Publicado: (2015)

The Importance of Natriuretic Peptides in Cardiometabolic Diseases
por: Vinnakota, Shravya, et al.
Publicado: (2020)

Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism
por: Glöde, Anja, et al.
Publicado: (2017)

Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model
por: Ameenuddin, Syed, et al.
Publicado: (2011)

CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart
por: Martin, Fernando L., et al.
Publicado: (2012)

Mutation of three amino acids in the disulfide-ring of a CNP based chimeric natriuretic peptide alters its vascular properties
por: Chen, Horng H, et al.
Publicado: (2009)

Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling
por: Ichiki, Tomoko, et al.
Publicado: (2017)

Progressive decline in circulating CNP with aging is associated with progressive cardiac fibrosis and myocardial impairment
por: Sangaralingham, Jeson, et al.
Publicado: (2009)

The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation
por: Schirger, John A, et al.
Publicado: (2009)

Innovative Therapeutics: Designer Natriuretic Peptides
por: Meems, Laura M.G., et al.
Publicado: (2016)

The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population
por: Cannone, Valentina, et al.
Publicado: (2013)

Designer natriuretic peptides for heart failure: advanced in clinical development
por: Burnett, John
Publicado: (2011)

Newer Insights into the Biochemical Physiology of the Renin–Angiotensin System: Role of Angiotensin-(1-7), Angiotensin Converting Enzyme 2, and Angiotensin-(1-12)
por: Ferrario, Carlos M., et al.
Publicado: (2009)

Modulating cGMP in heart failure by novel natriuretic peptides
por: Burnett, John C
Publicado: (2009)

Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System
por: Trask, Aaron J., et al.
Publicado: (2009)

The influence of aldosterone and angiotensin II on the diuretic effects of atrial natriuretic peptide in the isolated perfused rat kidney
por: Heringlake, M, et al.
Publicado: (1999)

C-type natriuretic peptide prevents angiotensin II-induced cardiac remodelling and dysfunction
por: Roloff, Konstanze, et al.
Publicado: (2015)

Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2021)

Commentary on “angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic”
por: Ferrario, Carlos M.
Publicado: (2020)

New angiotensins
por: Varagic, Jasmina, et al.
Publicado: (2008)

ACE2: Angiotensin II/Angiotensin-(1–7) Balance in Cardiac and Renal Injury
por: Varagic, Jasmina, et al.
Publicado: (2014)

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
por: Ferrario, Carlos
Publicado: (2009)

MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
por: Burnett, John C, et al.
Publicado: (2015)

Natriuretic Peptide Receptor-C Protects Against Angiotensin II-Mediated Sinoatrial Node Disease in Mice
por: Mackasey, Martin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_celjm2m9h460ko13tus7nrd73l